Questions in relation to Breast Cancer Treatment

Phil Early made this Rhyddid Gwybodaeth request to The Clatterbridge Cancer Centre NHS Foundation Trust as part of a batch sent to 217 authorities

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

Mae'r cais yn aros am eglurhad. Os Phil Early ydych chi, os gwelwch yn dda, mewngofnodi i anfon neges ddilynol.

Dear The Clatterbridge Cancer Centre NHS Foundation Trust,

I would like to please request the following information with regards to Breast Cancer Treatment.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

• Abemaciclib (Verzenios) + aromatase inhibitor *
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
• Alpelisib (Piqray) + Fulvestrant (Faslodex)
• Atezolizumab (Tecentriq)**
• Bevacizumab (Avastin)
• Eribulin (Halaven)
• Everolimus (Afinitor) + Exemestane
• Fulvestrant (Faslodex) as a single agent
• Gemcitabine + paclitaxel
• Herceptin (Trastuzumab) + paclitaxel
• Herceptin (Trastuzumab) as a single agent
• Lapatinib (Tyverb)
• Neratinib (Nerlynx)
• Olaparib (Lynparza)
• Palbociclib (Ibrance) + aromatase inhibitor*
• Palbociclib (Ibrance) + Fulvestrant (Faslodex)
• Pertuzumab (Perjeta) + trastuzumab + docetaxel
• Ribociclib (Kisqali) + aromatase inhibitor*
• Ribociclib (Kisqali) + Fulvestrant (Faslodex)
• Talazoparib (Talzenna)
• Trastuzumab emtansine (Kadcyla)
• Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

Thank you for answering these questions.

Yours faithfully,

Phil Early

FOI (THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST), The Clatterbridge Cancer Centre NHS Foundation Trust

Dear Phil Early

Re: Freedom of Information Request
Ref: 115-2022

Thank you for your email dated the 1st April, requesting information in relation to metastatic/advanced breast cancer treatment.

Your request is being treated as a new request under the terms of the Freedom of Information Act 2000 and we will endeavour to respond within twenty working days i.e. by no later than 29th April 2022.

If you have any queries about this request please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Kind regards

Naomi Frazer (she/her)
Information Governance Manager
[mobile number]

dangos adrannau a ddyfynnir

THOMAS, Sineesh (THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST), The Clatterbridge Cancer Centre NHS Foundation Trust

Dear Phil Early,

Please can you provide clarification on Question 2- Are you asking for patients received cycle 1, day 1 of each listed regimen?

Kind Regards

Sineesh Thomas
Information Governance Administrator

dangos adrannau a ddyfynnir

FRAZER, Naomi (THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST), The Clatterbridge Cancer Centre NHS Foundation Trust

2 Atodiad

Dear Phil Early

COVID-19 & Freedom of Information Requests

During this extraordinary period, The Clatterbridge Cancer Centre would
like to ask you for your patience and understanding when submitting a
request for business and corporate information under the Freedom of
Information Act 2000 (FOIA). At this time, our Trust is understandably
having to prioritise other areas and adapt our usual approach to these
requests during this pandemic. Although we endeavour to get this
information to you within the 20 working day timescale given under the
FOIA, as a result, please be aware that you may experience some delays in
receiving the information that you have requested. We would like to
apologise for any inconvenience that this may cause, and assure you that
we will get the requested information to you as soon as possible.

 

Re:  Freedom of Information Request

Ref:  115-2022

 

Thank you for your email dated the 1/4/2022, requesting information in
relation to breast cancer.

 

Your request is being treated as a new request under the terms of the
Freedom of Information Act 2000 and we will endeavour to respond within
twenty working days i.e. by no later than xx  xxxx 2022.

 

If you have any queries about this request please do not hesitate to
contact me.  Please remember to quote the reference number above in any
future communications.

 

Kind regards

Naomi Frazer

Information Governance Manager

Tel:  07426185889 (personal mob. Use temporarily)

 

[1]CCC email footer April 2021

 

 

dangos adrannau a ddyfynnir

Dear FRAZER, Naomi (THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST),

Hi Naomi
Yes, I can confirm that Question 2 relates to Cycle 1, Day 1

Yours sincerely,

Phil Early